Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven renal cell carcinoma~* CT-confirmed measurable disease~* Disease progression after bevacizumab +/- IFN~* Favorable/intermediate prognosis according to MSKCC~* Nephrectomy~* No contradictions to everolimus~* Age 18 or older~* Written informed consent~Exclusion criteria~* prior TKI's or mTOR inhibitor~* pregnant or nursing~* history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., New York Heart Association class III or IV)~* CNS metastases by neurologic exam and/or MRI~* local and/or systemic infections requiring antibiotics within 28 days prior to study entry~* other malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).